While the management of AMD, particularly its neovascular form (nAMD) characterized by choroidal neovascularization (CNV), has been significantly advanced by regular anti-vascular endothelial growth factor (anti-VEGF) intravitreal treatment (IVT), patient responses to these treatments vary considerably [1, 2]. This evidence concerns the gene VEGFA and choroidal neovascularization.